Literature DB >> 17803883

A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.

Sandhya Pruthi1, Judy C Boughey, Kathleen R Brandt, Amy C Degnim, Grace K Dy, Matthew P Goetz, Edith A Perez, Carol A Reynolds, Paula J Schomberg, James N Ingle.   

Abstract

New approaches to breast cancer treatment have enhanced clinical outcomes and patient care. These approaches include advances in breast irradiation and hormonal and systemic adjuvant therapies. In addition to the identification of new drug targets and targeted therapeutics (eg, trastuzumab), there is renewed re-emphasis in the development of biomarkers for the prediction of response to therapy. One example is the pharmacogenetics of tamoxifen metabolism and the individualization of hormonal therapy. The current treatment of breast cancer continues to evolve rapidly, with new scientific and clinical achievements constantly changing the standard of care and leading to substantial reductions in breast cancer mortality. The goal of this article is to provide clinicians who care for women with breast cancer a multidisciplinary, state-of-the art approach to the treatment of these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17803883     DOI: 10.4065/82.9.1131

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  9 in total

1.  Perceptions of care coordination in a population-based sample of diverse breast cancer patients.

Authors:  Sarah T Hawley; Nancy K Janz; Sarah E Lillie; Christopher R Friese; Jennifer J Griggs; John J Graff; Ann S Hamilton; Sarika Jain; Steven J Katz
Journal:  Patient Educ Couns       Date:  2010-11-12

2.  Racial and ethnic differences in adjuvant hormonal therapy use.

Authors:  Jennifer C Livaudais; Christopher Li; Esther M John; Mary Beth Terry; Mary Daly; Saundra S Buys; Laurel Habel; Beti Thompson; N David Yanez; Gloria D Coronado
Journal:  J Womens Health (Larchmt)       Date:  2012-06-25       Impact factor: 2.681

3.  Mammographic density as a predictor of breast cancer outcome.

Authors:  Gertraud Maskarinec; Christy G Woolcott; Laurence N Kolonel
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

4.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

Review 5.  Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?

Authors:  Francesco Bellanti; Bertil Kågedal; Oscar Della Pasqua
Journal:  Eur J Clin Pharmacol       Date:  2011-02-02       Impact factor: 2.953

Review 6.  Molecular targeted therapies for breast cancer treatment.

Authors:  Claus M Schlotter; Ulf Vogt; Heike Allgayer; Burkhard Brandt
Journal:  Breast Cancer Res       Date:  2008-07-24       Impact factor: 6.466

7.  ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.

Authors:  Xinxin Si; Yue Liu; Jinghuan Lv; Haijian Ding; Xin A Zhang; Lipei Shao; Nan Yang; He Cheng; Luan Sun; Dongliang Zhu; Yin Yang; Andi Li; Xiao Han; Yujie Sun
Journal:  Oncotarget       Date:  2016-04-12

8.  Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management.

Authors:  Sarah Rofaiel; Esther N Muo; Shaker A Mousa
Journal:  Pharmgenomics Pers Med       Date:  2010-09-17

9.  Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription.

Authors:  Shuai Chen; Han Wang; Zhi Li; Jun You; Qiu-Wan Wu; Can Zhao; Chi-Meng Tzeng; Zhi-Ming Zhang
Journal:  Br J Cancer       Date:  2018-05-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.